6598 Stock Overview
Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex diagnostic testing products for the In-Vitro diagnostics market.
Capture your thoughts, links and company narrative
Applied BioCode Corporation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$27.65|
|52 Week High||NT$37.65|
|52 Week Low||NT$23.20|
|1 Month Change||0.36%|
|3 Month Change||-1.60%|
|1 Year Change||-20.55%|
|3 Year Change||-74.63%|
|5 Year Change||-33.21%|
|Change since IPO||-60.22%|
Recent News & Updates
|6598||TW Medical Equipment||TW Market|
Return vs Industry: 6598 underperformed the TW Medical Equipment industry which returned 8.9% over the past year.
Return vs Market: 6598 underperformed the TW Market which returned 1.9% over the past year.
|6598 Average Weekly Movement||3.2%|
|Medical Equipment Industry Average Movement||4.6%|
|Market Average Movement||4.3%|
|10% most volatile stocks in TW Market||7.7%|
|10% least volatile stocks in TW Market||1.9%|
Stable Share Price: 6598 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 6598's weekly volatility (3%) has been stable over the past year.
About the Company
Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex diagnostic testing products for the In-Vitro diagnostics market. The company’s products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. In addition, It develops assays, such as BioCode SARS-CoV-2 Assay, a high volume automated nucleic acid multiplex assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; BioCode Respiratory Pathogen Panels, which simultaneously detects and differentiates the presence of 17 respiratory pathogens in nasopharyngeal swabs; BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and MDx assays pipeline for various molecular tests.
Applied BioCode Corporation Fundamentals Summary
|6598 fundamental statistics|
Is 6598 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6598 income statement (TTM)|
|Cost of Revenue||NT$154.69m|
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
|Earnings per share (EPS)||-1.98|
|Net Profit Margin||-38.58%|
How did 6598 perform over the long term?See historical performance and comparison